The US Clinical Research Market Outlook to 2017
With high unmet medical needs in therapeutic areas of Oncology and Central...
Upcoming SlideShare
Loading in …5
×

The US Clinical Research Market Outlook to 2017

480 views

Published on

With high unmet medical needs in therapeutic areas of Oncology and Central Nervous System disorders, the market is expected to witness several new drugs being developed for various medical conditions under these areas.

Published in: Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
480
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
4
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

The US Clinical Research Market Outlook to 2017

  1. 1. The US Clinical Research Market Outlook to 2017 With high unmet medical needs in therapeutic areas of Oncology and Central Nervous System disorders, the market is expected to witness several new drugs being developed for various medical conditions under these areas. The high frequency of chronic diseases along with associated increasing health care costs is driving the demand for clinical researches in the US. The country has rich history in medical innovation but off late due to decelerated pace of drug development, reduced government funding, inefficiency in conduct of clinical trials, the clinical research market in the country is experiencing slow growth. Despite of such changes, the therapeutic area of Oncology remains conclusively the most researched therapeutic condition followed by Central Nervous System disorders. The segment Breast Cancer draws maximum attention is expected to incline with a CAGR of 22.8% during the period of 2012-2017. Further, the areas of Alzheimer and Multiple Sclerosis are expected to witness new drugs on account of unmet medical needs in these areas. The market for clinical research in the country showcased a CAGR of 11.7% during 2006-2012 and will witness off shoring of many clinical trials to emergent markets such as China, Latin America and Brazil on account of increasing cost of conducting trials in the US. The market on account of patent expiry of several branded drugs and increased strategic alliances between pharma companies and CRO is projected to escalate with a CAGR of 15.8% during the period of 2012-2017. “The drug development pipeline for multiple sclerosis is expected to improve. The new drugs such as laquinimod, teriflunomide and dimethyl fumarate, and three mAbs— alemtuzumab, daclizumab and rituximab are anticipated to mask the effects and remit the occurrence of multiple sclerosis” - according to the research report ‘The US Clinical Research Market Outlook to 2017’ from Ken Research. According to the report, early detection and screening are considered to be one of the best ways to lower the risk of dying from Breast Cancer. The increased numbers of clinical trials have helped women in the country to use the advance clinical support. Clinical trials are being conducted in the country to determine the underlying cause of the disease and identify a cure to the disease. The report “The US Clinical Research Market Outlook to 2017” provides detailed overview on the clinical research market of the US. This report helps reader to identify the ongoing trends in the industry and anticipated growth in future depending upon changing industry dynamics in coming years. The report will help industry consultants, pharma companies, CROs and other stakeholders to align their market centric strategies according to ongoing and expected trends in future. For more information on the industry research report please refer to the below mentioned link: http://www.kenresearch.com/healthcare/trials-and-diagnostic-services/us-clinical-research-market- outlook/390-91.html

×